Stay updated on IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a Phase II study of IMMU-132 alone or with carboplatin for triple-negative breast cancer, including its study details, eligibility criteria, and withdrawn status.SummaryDifference36%

- Check18 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the study page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedThe study record view now displays a 403 Forbidden message with a Home link, while a notice about NIH website changes appears above the page.SummaryDifference2%

- Check32 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check39 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previous study record content with an access-denied message. This indicates that the study's details are no longer publicly accessible through the current page.SummaryDifference16%

Stay in the know with updates to IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.